GLP-1s Are Changing CKD Progression. Nephrology Clinics Need to Adjust Their Business Model.

For years, many nephrology practices have built their operating model around later-stage kidney disease: advanced CKD, dialysis preparation, transplant coordination, and high-acuity patient management. That work will remain essential. However, the clinical landscape is shifting. GLP-1 receptor agonists, particularly semaglutide, are now showing meaningful evidence in slowing chronic kidney disease progression, especially in patients with type 2 diabetes and CKD. The business implication is clear: nephrology clinics can no longer rely only on a model centered around the sickest patients. They will need to move earlier in the disease journey and build more preventive, longitudinal care models.

The evidence behind this shift is becoming difficult to ignore. In the FLOW trial published in The New England Journal of Medicine, researchers concluded that semaglutide “reduced the risk of clinically important kidney outcomes” in patients with type 2 diabetes and chronic kidney disease. A broader meta-analysis also found that GLP-1 receptor agonists “significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.” These are not minor developments. They suggest that a growing portion of CKD care may move upstream, with more emphasis on slowing decline, managing risk factors, coordinating medications, improving adherence, and keeping patients stable longer.

This does not mean nephrology becomes less important. It means nephrology becomes important earlier. If GLP-1s delay progression, reduce kidney-related events, and help patients avoid dialysis or transplant for longer, clinics must adapt from an episodic, late-stage model to a more proactive care management model. The winners will be practices that can identify CKD patients earlier, monitor them more consistently, manage comorbidities more effectively, and coordinate care between nephrology, primary care, endocrinology, cardiology, pharmacy, and nutrition.

CMS ancillary programs such as Chronic Care Management, or CCM, are well positioned for this transition. CMS defines CCM as managing patients with “multiple (2 or more) chronic conditions expected to last at least 12 months.” That description fits many nephrology patients, who often present with CKD alongside diabetes, hypertension, heart disease, obesity, or other chronic conditions. CCM also supports the kind of non-face-to-face care that preventive nephrology requires, including care coordination, medication review, patient follow-up, care plan updates, and ongoing monitoring between visits.

This is where nephrology clinics have a meaningful strategic opportunity. A patient on a GLP-1 may still need kidney function monitoring, lab review, medication reconciliation, dietary guidance, blood pressure support, diabetes coordination, adherence management, and risk stratification. These activities are not always captured well in a traditional office-visit model. CCM allows practices to build a more durable monthly care infrastructure around those patients, rather than waiting until the patient deteriorates and requires more intensive intervention.

The FDA approval of Ozempic for type 2 diabetes and CKD further reinforces this direction. The National Kidney Foundation described the approval as “an important milestone in kidney disease treatment,” noting that it offers a new option to reduce complications such as heart disease, dialysis, or kidney transplant. That is exactly why the business model needs to evolve. If therapy is moving toward slowing disease progression, the care model must move toward prevention, coordination, and long-term patient management.

For nephrology practices, this shift creates both a risk and an opportunity. The risk is that clinics remain built around a legacy model where revenue, staffing, and patient engagement are heavily tied to late-stage disease activity. The opportunity is to develop a broader CKD management platform that supports patients before they reach crisis points. CCM, Remote Patient Monitoring, Principal Care Management, nutrition support, medication adherence programs, and structured care coordination can all become part of a more modern nephrology operating model.

Practically, this means clinics should begin asking several strategic questions. Which CKD patients are eligible for CCM today? Which patients are on GLP-1 therapy and need structured kidney monitoring? Are workflows built to manage patients monthly, or only when they come into the office? Is the EHR configured to support care plans, time tracking, documentation, and billing compliance? Does the practice have the staffing model to support recurring care management? Are patients being educated on how GLP-1 therapy fits into broader CKD risk reduction?

The future of nephrology will not be defined only by dialysis starts or late-stage interventions. It will increasingly be defined by how well clinics manage chronic risk over time. GLP-1s are accelerating that change by giving patients and providers more tools to delay CKD progression. For nephrology practices, the strategic response should not be passive. It should be operational.

The clinics that adapt will build care models around prevention, longitudinal engagement, and CMS-supported ancillary services. They will use CCM not simply as a billing code, but as a framework for managing CKD patients earlier, more consistently, and more profitably. As GLP-1s slow the progression of kidney disease, nephrology clinics must shift from a business model focused primarily on the sick to one built around keeping patients healthier for longer.

Source support for the quoted claims: the NEJM FLOW trial concluded semaglutide reduced clinically important kidney outcomes and cardiovascular death in patients with type 2 diabetes and CKD. (New England Journal of Medicine) The Lancet Diabetes & Endocrinology meta-analysis reported evidence that GLP-1 receptor agonists reduce clinically important kidney events, kidney failure, and cardiovascular events. (PubMed) The National Kidney Foundation notes the January 28, 2025 FDA approval of Ozempic for people with type 2 diabetes and kidney disease. (National Kidney Foundation) CMS defines CCM around multiple chronic conditions expected to last at least 12 months and describes CCM as non-face-to-face care coordination services billed monthly. (cms.gov)